Literature DB >> 25412391

Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system.

Vivien W Chen1, Mei-Chin Hsieh, Mary E Charlton, Bernardo A Ruiz, Jordan Karlitz, Sean F Altekruse, Lynn A G Ries, J Milburn Jessup.   

Abstract

BACKGROUND: The Collaborative Stage (CS) Data Collection System enables multiple cancer registration programs to document anatomic and molecular pathology features that contribute to the Tumor (T), Node (N), Metastasis (M) - TNM - system of the American Joint Committee on Cancer (AJCC). This article highlights changes in CS for colon and rectal carcinomas as TNM moved from the AJCC 6th to the 7th editions.
METHODS: Data from 18 Surveillance, Epidemiology, and End Results (SEER) population-based registries were analyzed for the years 2004-2010, which included 191,361colon and 73,341 rectal carcinomas.
RESULTS: Overall, the incidence of colon and rectal cancers declined, with the greatest decrease in stage 0. The AJCC's 7th edition introduction of changes in the subcategorization of T4, N1, and N2 caused shifting within stage groups in 25,577 colon and 10,150 rectal cancers diagnosed in 2010. Several site-specific factors (SSFs) introduced in the 7th edition had interesting findings: 1) approximately 10% of colon and rectal cancers had tumor deposits - about 30%-40% occurred without lymph node metastases, which resulted in 2.5% of colon and 3.3% of rectal cases becoming N1c (stage III A/B) in the AJCC 7th edition; 2) 10% of colon and 12% of rectal cases had circumferential radial margins <1 mm; 3) about 46% of colorectal cases did not have a carcinoembryonic antigen (CEA) testing or documented CEA information; and 4) about 10% of colorectal cases had perineural invasion.
CONCLUSIONS: Adoption of the AJCC 7th edition by the SEER program provides an assessment tool for staging and SSFs on clinical outcomes. This evidence can be used for education and improved treatment for colorectal carcinomas.
© 2014 American Cancer Society.

Entities:  

Keywords:  AJCC; collaborative stage; colon; prognostic site-specific factors; rectum

Mesh:

Substances:

Year:  2014        PMID: 25412391      PMCID: PMC4239669          DOI: 10.1002/cncr.29056

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.

Authors:  Fortunato Ciardiello; Sabine Tejpar; Nicola Normanno; Domenica Mercadante; Tracey Teague; Bruno Wohlschlegel; Eric Van Cutsem
Journal:  Target Oncol       Date:  2011-06-01       Impact factor: 4.493

Review 2.  The structure, metabolism and function of the carcinoembryonic antigen gene family.

Authors:  P Thomas; C A Toth; K S Saini; J M Jessup; G Steele
Journal:  Biochim Biophys Acta       Date:  1990-12-11

3.  Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases.

Authors:  B Cady; M D Stone; W V McDermott; R L Jenkins; A Bothe; P T Lavin; E J Lovett; G D Steele
Journal:  Arch Surg       Date:  1992-05

4.  Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007.

Authors:  Amanda I Phipps; John Scoggins; Mary Anne Rossing; Christopher I Li; Polly A Newcomb
Journal:  Am J Public Health       Date:  2012-01-19       Impact factor: 9.308

Review 5.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

6.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

7.  ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.

Authors:  Roscoe F Morton; Elizabeth H Hammond
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

8.  Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III.

Authors:  E J Th Belt; M F M van Stijn; H Bril; E S M de Lange-de Klerk; G A Meijer; S Meijer; H B A C Stockmann
Journal:  Ann Surg Oncol       Date:  2010-07-13       Impact factor: 5.344

9.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

Authors:  Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer
Journal:  CA Cancer J Clin       Date:  2008-03-05       Impact factor: 508.702

Review 10.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

View more
  27 in total

1.  Comparison of model fit and discriminatory ability of the 8th edition of the tumor-node-metastasis classification and the 9th edition of the Japanese classification to identify stage III colorectal cancer.

Authors:  Kei Kitamura; Dai Shida; Shigeki Sekine; Yuka Ahiko; Yuya Nakamura; Konosuke Moritani; Shunsuke Tsukamoto; Yukihide Kanemitsu
Journal:  Int J Clin Oncol       Date:  2021-06-03       Impact factor: 3.402

2.  Revisiting Dukes' paradigm; some node positive colon cancer patients have better prognosis than some node negative patients.

Authors:  O Abdel-Rahman
Journal:  Clin Transl Oncol       Date:  2017-10-30       Impact factor: 3.405

3.  Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays.

Authors:  Katrin Tiemann; Carolina Garri; Jeffrey Wang; Lauren Clarke; Kian Kani
Journal:  J Vis Exp       Date:  2018-09-19       Impact factor: 1.355

4.  Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.

Authors:  Y F Song; Z B Xu; X J Zhu; X Tao; J L Liu; F L Gao; C L Wu; B Song; Q Lin
Journal:  Clin Transl Oncol       Date:  2016-10-14       Impact factor: 3.405

5.  Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with siRNA against ELFN1-AS1 suppress colon adenocarcinoma proliferation and migration.

Authors:  Liyang Dong; Chao Ding; Tingting Zheng; Yanan Pu; Jiameng Liu; Wenzhe Zhang; Fei Xue; Ping Kang; Yongbin Ma; Xuefeng Wang; Chaoming Mao
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

6.  Hospital Characteristics Associated with Stage II/III Rectal Cancer Guideline Concordant Care: Analysis of Surveillance, Epidemiology and End Results-Medicare Data.

Authors:  Mary E Charlton; Jennifer E Hrabe; Kara B Wright; Jennifer A Schlichting; Bradley D McDowell; Thorvardur R Halfdanarson; Chi Lin; Karyn B Stitzenberg; John W Cromwell
Journal:  J Gastrointest Surg       Date:  2015-12-09       Impact factor: 3.452

Review 7.  Assessment of lymph node involvement in colorectal cancer.

Authors:  Mark L H Ong; John B Schofield
Journal:  World J Gastrointest Surg       Date:  2016-03-27

8.  Meprin α combined with CEA and CA19-9 improves prognostic prediction for surgically treated colorectal cancer patients.

Authors:  Hongfa Hou; Xinmin Gou; Juyuan Bu; Yonghui Su; Xinying Wei; Xiao Wang; Bingzong Hou
Journal:  Int J Clin Exp Pathol       Date:  2017-10-01

9.  Overexpression of mRNA-decapping enzyme 1a affects survival rate in colorectal carcinoma.

Authors:  Chuanqing Wu; Weizhen Liu; Tuo Ruan; Xiaojie Zhu; Kaixiong Tao; Weikang Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

10.  Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.

Authors:  Jingtao Wang; Xiao Wang; Fudong Yu; Jian Chen; Senlin Zhao; Dongyuan Zhang; Yang Yu; Xisheng Liu; Huamei Tang; Zhihai Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.